As we emerge into the post-genome era, proteomics finds itself as the driving force field as we translate the nucleic acid information archive into understanding how the cell actually works and how disease processes operate. Even so, the traditionally held view of proteomics as simply cataloging and developing lists of the cellular protein repertoire of a cell are now changing, especially in the sub-discipline of clinical proteomics. The most relevant information archive to clinical applications and drug development involves the elucidation of the information flow of the cell; the "software" of protein pathway networks and circuitry. The deranged circuitry of the cell as the drug target itself as well as the effect of the drug on not just the target, but also the entire network, is what we now are striving towards. Clinical proteomics, as a new and most exciting sub-discipline of proteomics, involves the bench-tobedside clinical application of proteomic tools. Unlike the genome, there are potentially thousands of proteomes: each cell type has its own unique proteome. Moreover, each cell type can alter its proteome depending on the unique tissue microenvironment in which it resides, giving rise to multiple permutations of a single proteome. Since there is no polymerase chain reaction equivalent to proteomics-identifying and discovering the "wiring diagram" of a human diseased cell in a biopsy specimen remains a daunting challenge. New micro-proteomic technologies are being and still need to be developed to drill down into the proteomes of clinically relevant material. Cancer, as a model disease, provides a fertile environment to study the application of proteomics at the bedside. The promise of clinical proteomics and the new technologies that are developed is that we will detect cancer earlier through discovery of biomarkers, we will discover the next generation of targets and imaging biomarkers, and we can then apply this knowledge to patient-tailored therapy.
Introduction
The enthusiasm of the final success in deciphering the entire human genome (1, 2) has faded slightly and has given rise to the post-genome era with a more tempered way of thinking: The genome is undoubtedly the blueprint of life, the information archive, but it is the proteome which makes life happen and does most of the work of the cell. All cellular metabolic aspects, the whole cellular response, diseases and even cancer are caused by alterations in protein expression. Predictions of protein expression from the genomic point of view can only be partial (3, 4) , even when changing to mRNA expression levels (5, 6) as the correlation between mRNA levels and corresponding protein expression is often poor (7, 8, 9, 10) . The importance of post-translational modifications (11) of proteins to change or even enable their metabolic role can not predicted from knowledge achieved from the DNA and mRNA levels, yet. Therefore science has chosen another challenge to conquer, the decryption of the human proteome.
The proteome is by definition (12) the totality of all proteins expressed in a cell, in contrast to the genome, which comprises the whole cellular DNA its analysis was called proteomics. Starting from this definition and realizing the enormous complexity of human life we have to deal with a very great number of different proteins. The analyzing tools are based on traditional protein biochemistry. As there is no polymerase chain reaction equivalent in proteomics, which could deliver unlimited amounts of sample material, the traditional methods are linked to miniaturized high throughput methods. The first attempt to handle the proteome was early achieved (13, 14) with the invention of 2D-gel electrophoresis. Optimizing handling as well as reproducibility by mainly Görk and others (e.g. reviewed in 15) revealed its analytical value even today. The invention of matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI TOF MS) in the late 80's (16) helped to solve problems that traditional mass spectrometry had limitations with. Using the traditional high-energy ionization method, high molecular weight proteins, especially those with biological impact, are altered, fragmented or even totally destroyed before they could be analyzed. This ionization method is replaced by a much more careful transfer of protons via the matrix (17), a so-called soft ionization. Shortly after the development of these techniques occurred, attempts to miniaturize and format them for high throughput were performed. The miniaturization and throughput is necessary to examine small amounts of tissue, which are delivered by e.g. human biopsy material, and the wish for handling large amounts of samples for screening purposes. As soon as the number of analyzed samples reaches a critical mass and the amount of generated data increases in the same way, the need for a solid bioinformatic analysis tool becomes urgent.
Predictive, Diagnostic and Therapeutic Value of the Proteome
The knowledge of the proteome partially, allows us to have a look into basic mechanisms of life. Knowing the alterations on protein level enables the analysis of diseases and cellular response pathways, respectively. In contrast to this more mechanistic approach the search for and use of marker proteins as molecular profiling tools is becoming more and more important. As diseases and even cancer are affected by alterations in protein expression, a certain protein, which is always affiliated with a certain kind of tumor, becomes a valuable diagnostic tool. In recent literature the growing number of studies with this background proves the importance of this approach (e.g. 18, 19, 20, 21) . To find such a unique marker protein the proteomes of a malignant sample must be compared with the corresponding healthy sample. This results in a couple of protein candidates. These candidates might all be specific marker proteins for this particular disease for the tissue-donating patient. Their predictive value for another patient may be nearly zero. The analysis and comparison of the proteome of lots of different patients to eliminate the patient-to-patient proteomic variability caused by gender, age, nutrition, ethnicity and general health status has to be done. After crosschecking all patients' proteome-profiles against each other, one patient -independent but tumor -specific marker protein might be distilled. This marker protein is suitable as a diagnostic marker for future patients. In case of being generated out of a biopsy, this tumor marker protein could be used to validate a traditional pathologic diagnosis at an H&E stained section of a biopsy. After this special protein is spotted once, one can start to search for it in body fluids, e.g. serum, plasma or urine. Due to today's high sensitive methods of protein analysis the recovery of low abundant proteins in serum can be performed in a routine examination. The value of a marker protein present in body fluids as well is much higher than for a tissue related marker: first of all the acceptability for the patient is much higher, as blood drawing is a daily routine event, whereas biopsy especially in conjunction with endoscopy is much more critical. The second aspect is even more important as examining body fluids matches a whole body screening whereas procuring a biopsy needs localization, first. Therefore analyzing the body fluids is a suitable and versatile tool in diagnosis of small in situ carcinoma and maybe even early stages, as well.
Recently the concept of serum-based proteome pattern diagnosis has been described (22) where a mass spectrometrygenerated proteome profile is analyzed by an artificial intelligence-based algorithm to find the hidden patterns of combinations of markers that can discriminate healthy from cancer patients. In contrast to biomarkers, examining the proteome for new therapeutic targets is more difficult. An intriguing aspect of this technique is that the underlying identity of the protein needs not to be known the pattern itself is the diagnosis. This technique allows the clinical investigator to exam incoming patients serum patterns to known cancer and healthy patterns to find out which class the unknown belongs to. This technique has shown remarkable sensitivity and specificity with ovarian and other cancers. The beginning is the identification of its protein identity; therefore a tailored drug could be designed and synthesized. More easily is to perform an antibody-based therapy with an antibody suited for a prominent epitope of the tumor marker protein. A cytostatic drug can be linked to the other arm of the antibody; therefore the specificity of the antibody is coupled with the efficiency of a broadband cytostaticum. The main advantage of this tumor treatment in comparison to traditional treatment modalities is its very high specificity (vs. chemotherapy, radiation) and its coverage in reaching every tumor cell (vs. surgery, radiation).
Sample Preparation
A major problem when dealing with sample preparation for tissue and clinical based proteomics is the inherent sample heterogeneity. In the case of a tumor biopsy it will contain the interesting three-dimensional structure of the diseased tissue. On the other hand the biopsy contains surrounding normal tissue as well in addition to epithelial, endothelial and connective tissue and infiltrating lymphocytes. When lysing this whole conglomerate the interesting tumor epithelial proteins will be diluted and contaminated with the proteomes of the other resident cell types. The hope that the unaffected control biopsy will represent the same combination of cell morphology and therefore contain the same combinations of proteomes of unwanted proteins is not practical (23), and is a poor attempt to handle the basic problem of tissue heterogeneity.
There have been attempts to circumvent these problems. After careful tissue homogenization, the tumor cells can be separated by antibody -linked magnetic separation techniques (24). These promising techniques require initial cell selection. As the goal of the analysis is the unbiased search for a marker protein this initial discrimination becomes a pre-selection and therefore might limit the value of the following proteomic analysis. Another approach is the establishment of primary or immortalized cell cultures from a biopsy (25). The advantage of "unlimited" biological material is escorted by the significant differences between in vivo and in vitro: The cellular proteome is a sensitive indicator of general biologic activity, metabolism and disease status. Therefore it reflects and is influenced by the important aspects of three dimensional tissue architecture. The resulting cellular microenvironment goes along with cell-cell contact, extracellular matrix, autocrine & paracrine growth factors, vascular & lymphatic circulation, cytokine response and interaction of different cell types (26). These parameters cannot be simulated in vitro using a cell line, yet. Therefore published results (27) dealing with proteome differences of biopsies vs. corresponding cell lines are not surprising.
The only way to directly address this problem is to micro-dissect the material after preparing frozen cryostat sections. To take advantage of the complex tissue architecture it is necessary to use consecutive sections were every 10 th section is H&E stained for diagnostic purposes. From two consecutive H&E stained sections, the tissue architecture of the interven-ing 9 unstained sections can be estimated. Microdissection is a well-known tool from genomic orientated research and was adapted to proteomics without any major alterations. For large tissue areas, manual microdissection using syringe needles and transferring is the method of choice. Handling under a low magnifying binocular microscope is required. As soon as the areas of interest become smaller, a laserassisted microdissection becomes mandatory. From the two most important and independent methods to transfer/collect the desired sample (laser pressure catapulting, LPC (28) and laser capture microdissection, LCM (29, 30)). Since LCM allows for direct procurement isolation of the cells of interest, LCM seems to have become the preferred tool for proteomics ( Figure 1 ). After cryostat sectioning, fixation in 70% ethanol and hematoxylin staining, the glass slide is placed on the LCM device. It consists of a regular microscope with a laser attached to it. Directly on top of the tissue a small plastic cap is placed. The cap is covered with a thin ethylene vinyl acetate polymer sheet with low melting temperature capabilities. The regions of interest are focused and irradiated with the IR laser beam. The laser is focused to a spot between 6-30 µm diameter and its energy melts the tissue adherent surface of the plastic sheet. Therefore the sheet glues onto the tissue for this certain area. After removal of the cap a circular disk of the tissue with 6-30 µm diameter representing one laser shot is ripped out of the whole section and therefore collected onto the cap. As the tissue is not altered by high energy laser irradiation or directly cut by heat of a UV Laser, this is a sparing method for microdissecting tissue. The cap is designed to fit as a lid for routine Eppendorf centrifuge cups, which enables subsequent lysis of the attached tissue areas. Depending on the proteome techniques employed 5,000 (e.g., protein arrays, ELISAs) to 30,000 (e.g., 2D-PAGE analysis) shots may be needed.
Sample preparation itself has to be performed with care, as temperature and time are important details affecting protein preservation. As soon as the cryostat section is cut from the whole tissue, the clock begins ticking as proteases and phosphatases can begin to markedly affect the proteome. The whole tissue block itself can easily be stored at -80º C for many years. The sections can only be stored over short time periods, as their ratio surface/volume is much higher and therefore proteolysis even at -80º C becomes a problem. The final sample preparation itself has to be performed at room temperature or in an ice bath. According to the Arrhenius equation, proteolysis is now a serious issue. To avoid proteolysis it is necessary to work fast and to add protease inhibitors. Until the tissue is not lysed in the lysis buffer these protease inhibitors have to be present in all aqueous solutions the section is immersed in (fixation, staining, washing…).
The final sample lysis is as important as the microdissection itself, as quality of lysis influences resulting analysis. The lysis buffer can be a mixture of different components, or to minimize interferences with the assay, consist of only one reagent. A routine buffer for 2D gel electrophoresis contains normally high amounts of urea (up to 9 M) as a chaotrophic component. Nonionic detergents (CHAPS, Triton X100) enhance solubility of membrane proteins, reducing agents (DTT) are taking care of disulfide bonds. Finally addition of ampholites (zwitterionic reagents) adjusts and buffers the pH. For direct mass spectrometry a complete different lysis philosophy is required, as a cocktail of reagents will interfere with the matrix and the resulting mass spectrum. Therefore lysis in 1% Nonidet NP40 solution is an often practiced protocol.
Tools for Tissue Proteome Analysis

2D-gel Electrophoresis
The first method of separating and analyzing large numbers of different proteins was the 2D-gel electrophoresis under denaturing conditions. In the first dimension a separation according to the isoelectric point (IEP) is performed by adding the lysate onto an immobilized pH-gradient and applying a gel electrophoresis up to 90,000 Vhrs with voltages up to 8,000 V. The second dimension separates the pro-teins within a polyacrylamide gel depending on their molecular size, thus correlating with their molecular weight. After fixation and proper staining (silver staining or fluorescent staining) each single protein appears as a distinct spot in the gel. Starting from a typical cell lysate of approximately 75,000 cells (15,000 shots) at least 1500 spots should appear on a regular gel. Actually the number of proteins is much higher but resolution is limited. An attempt to handle comigration and other resolution decreasing phenomena is the use of "zoom-gels" which focus onto a narrow pH-range. Out of yeast homogenate 2700 spots could be detected as a pH-range of 0.7 units was expanded to 18 cm (31). Visual or software based analysis of different expression between e.g. tumor and normal samples provide a differential expression. Each single spot represents a highly-purified protein and can be punched out of the gel for further analysis (32). Until the invention of MALDI the next step was to run lots of gels in parallel to pool enough spots, therefore protein, to perform an Edmann sequencing for finally analyzing the protein identity by its sequence (33). Nowadays one prominent spot delivers sufficient amounts of protein to allow sequencing by mass spectrometry. After tryptic digestion of the protein the couple of fragments deliver a protein specific fingerprint, which for about 50%of all proteins is sufficient to correlate it to a completely sequenced protein in a database. Sequencing of major fragments by advanced MS-methods is effectual to find the protein in databases, as the decryption of the human proteome rapidly continues. N the future, multiplexed inline liquid chromatographic separation systems coupled directly to mass spectrometry (LC-LC-LC-MS/MS) with and without affinity tagging are being developed and may someday replace gel-based systems such as 2D-PAGE (34-40).
SELDI TOF MS
As 2D gel electrophoresis requires large amounts of proteins and is a very time consuming procedure (41,42), other methods for high sensitivity high throughput screening have been developed. The high number of proteins within a whole cell lysate can only be insufficiently handled by MALDI: Too many proteins with comparable masses influence each other in the resulting mass spectrum, they can influence the matrix assisted soft ionization with protons and they can even hide some other proteins completely. Ion signal suppression is a huge problem for clinical analysis of complex mixtures by MALDI, as the most abundant ionizing proteins can swamp the signal of all other proteins. Therefore a reproducible fractionating of a whole cell lysate is required. Fractionating proteins according to their chemical properties (IEP, affinity to reversed phase or to affinity-tagged surfaces) is a wellknown procedure in protein chemistry. Attempts to miniaturize sample volume (using very small chromatographic columns) and optimize sample recovery from the assays are still in process. A technological breakthrough combining chromatographic active surfaces with an interface ("chips") for MALDI was achieved in the 90's. This was called surface enhanced Laser desorption ionization (SELDI) and was first described by Hutchens and Yip (43) . With only 1 µl of sample a high-resolution mass spectrum following a complete chromatographic separation can be performed ( Figure  2) . Using a robot for all subsequent washing, loading and incubating steps allows a high throughput screening of at least 192 samples within 9 hrs. Following all experimental steps a mass spectrum for each surface determined (e.g. ion exchange, reversed phase, biologic activated surface) fraction results. Every peak represents the "mass over charge" value of one single protein.
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Comparing different spectra may give a differential protein expression between different samples. As the spectra are generated in a high reproducible way the protocols used for searching for the tumor marker can used for diagnosing future samples, as well. This technology has been employed successfully by investigations coupling LCM to SELDI analysis for molecular profiling studies of human cancer (Figure 3 ) (44) SELDI analysis also has been used in biomarker discovery from body fluids (21) and gross tissue based analysis (45). Molecular profiling studies directly from tissue specimens has also been achieved using a novel "imaging mass spectrometry" platform (46). This new technology can query an entire tissue specimen using a scanning MALDI-TOF device so that protein identification is obtained concomitantly with cellular localization for 3-D imaging.
Tissue and Protein Arrays
SELDI is an approach to screen for patterns of unknown proteins in samples, as the underlying protein identity is not needed to generate the mass over charge proteomic fingerprints. The entire field of protein microarray technology is significantly different, as the final analysis is largely performed using antibodies with pre-characterized specificity. Therefore this approach is used not for discovery so much as for screening and profiling -especially well-suited for the and analysis of signaling pathways.
Arraying in proteomics is based on well-known array techniques from genomics. ping of the epitopes the visualization is performed by wellknown techniques of immune histochemistry (e.g. DAB staining). The analysis can be done by acquisition with highresolution CCD-camera scanners or for higher dot densities with laser scanners. The high number of spots per slide, which are analyzed simultaneously, allows a very high sample number per run, which is requested for performing clinical trials with large case numbers. A new type of protein array has recently been developed and described (48) in which LCM procured cancer cells are lysed and arrayed directly on nitrocellulose covered slides (Figure 4 ). These arrays have had profound impact on the study of signal pathways in human cancer biopsy specimen, as they are tremendously sensitive. A few hundred cells gives rise to dozens of arrays, and therefore dozens of analytes can be examined. These arrays also have the distinct advantage of each lysate being arrayed in a miniature dilution curve so that every analysis is performed in the linear dynamic range of the antibody-antigen reaction. It enables the usage of lysate dilution curves for every sample (48), although. This assay design conquers then the danger of protein overload and therefore saturation problems with the following immunohistochemistry, as the sample volumes used for arraying are often too precious or too small for a protein content determination. The arrays themselves can be purchased from certain manufactures, often even as a custom made design, and the arrayer are commercially available as well.
Tissue arrays are a rather new development, which combines the advantage of high throughput analysis with the benefit of preserved histological information. Using a needle punch (0.6 mm diameter) up to 1000 cylinders from different fixed and paraffin embedded tissue blocks can be excised, transferred to a paraffin donor block and combined in an array like pattern (49). Consecutive sections are transferred onto glass slides and are processed using standard methods of immune histochemistry to check for antigen expression. To counter tissue heterogeneity even within consecutive sections, it is possible to use the same samples in triplicate. This ensures the examination of the areas of interest of the original tissue block. The final analysis following immunohistochemistry and DAB staining is performed visually by traditional light microscopy. Therefore "quantification of antigen expression" becomes a crucial issue. Guaranteeing objectivity is performed when at least two different pathologists estimate DAB staining intensity as well as staining pattern.
Bioinformatics
In the late 1980s and the beginning 1990s the term bioinformatics was established and gained popularity (50). This was a markedly event as final analysis or processing of data up to date was part of the experiment itself and not an independent science. This change in the point of view was arousing in parallel as the amount of data to analyze increased dramatically.
The purpose of bioinformatics is not to acquire, sort, organize, store and finally find again huge amounts of computer generated or computer processed data, but to find a way to distill valuable information out of the flood of information gained. To handle this "needle in the haystack" problem, algorithms are used to compare different datasets in an automated and iterative way with each other. New types of bioinformatics data mining systems are constantly being developed, but most fall into two main type of approaches: i) Supervised Systems: These approaches require a body of knowledge or data where outcome is already known to train on. Example systems are linear regression models, non-linear feed-forward neural networks (NLFN), and genetic algorithms (GA's) (51-57) ii) Unsupervised Systems: The tools cluster data without previous knowledge of outcome or classification. Example approaches are K-means nearest neighbor analysis, Euclidean distance based non-linear methods, fuzzy pattern matching methods and self-organizing mapping (SOM's) (58) (59) (60) . The problem however is the same for any approach, which is finding optimal feature sets in a large unbounded information base (the proteome).
Bioinformatics allows the search for protein identity in databases after peptide mass fingerprinting of digested proteins following 2D gel electrophoresis. The number of entries in these databases is growing permanently therefore the chance for a match without complete sequencing is increasing.
This problem is most evident when one considers the blood or serum proteome -an information archive that is mostly unexplored. The blood proteome is constantly changing as a consequence of the perfusion of the disease process, which adds to, subtracts from, or modifies the circulating proteome. These differences may be the result of proteins being overexpressed and/or secreted and shed into the milieu or clipped or modified as a consequence of the disease process, or even subtracted from the proteome due to proteolytic degradation pathway activation. Quaternary effects due to protein-protein interaction and protein complex formation can also modify and change the circulating serum proteome. Using SELDI-TOF technology, a drop of blood from patients can be analyzed) to created a proteomic signature of the serum (Figure 4 ). The information content of only a small window of the proteome (less than 20,000 m/z) is enormous and is comprised of thousands of protein ion signatures, (up to 15,500 data points). Artificial-intelligence (AI) based bioinformatics that is vigilant, since it adapts and gains experience over time, is well-suited for this kind of data mining because of the huge dimensionality of the proteome itself. Application of these AI systems to mass spectral data derived from the serum proteome has given rise to a new analytical paradigm: proteomic pattern diagnostics. Using this approach we use a genetic algorithm to search though the 15,500 data points by dividing the data into subsets of 5 to 20 randomly chosen m/z values (22). The algorithm sorts through combinations of protein signatures within the training set until it finds through mating and recombining the data, the best, or most "fit " combination of proteins whose combined relative intensity values plotted in n-space differentiate the training set into homogenous clusters of data. The value of using a genetic algorithm to mine the data is best illustrated by the fact that the datstream of 15,500 datapoints, divided into packages of 5-20 values creates 15,500 5 to 15,500 20 combinations, or about 1.5 billion to 1.5 trillion trillion (1.5 24 ) patterns. If one was to explore each of these combinations one at a time, it would take a computer performing one billion operations per second over 47 million years to find the most fit solution. GA's can find solutions in these unbelievably huge sets in only a few days through the iterative re-mating and recombination process using "selective pressure" through a fitness test. In this instance the fitness test is an unsupervised SOM-based adaptive clustering program. An interesting paradigm that arises from this process is that as each new patient is validated through pathologic diagnosis, the serum proteomic signature can be added to an ever-expanding training set ( Figure 5 ). In fact, it is possible to generate not just one, but multiple combinations of proteomic patterns from a single mass spectral training set, each pattern combination readjusting as the models get better in the adaptive mode.
Future Developments
A major goal of clinical proteomics is the elucidation and understanding of disease-altered protein-protein interactions that rewire the cellular circuitry. Understanding how this circuitry changes and reconnects as the disease process unfolds, would enable selection of a patient -tailored and targeted therapeutic, and is envisaged to provide molecular knowledge about how the patient responds to the therapy (61). Figure 5 : Ever-expanding training sets for proteomic pattern analysis. As newly validated patient-derived spectra is added over time to a growing population of data, artificial intelligence analysis learns and gains experience from the clustering outcome. It is envisioned that the patient data can be brought in over the internet from remote site point-of-care locations and inserted into a central data repository for analysis and the diagnosis returned back electronically.
Combinatorial therapy, where either selected "nodes" or an entire signaling pathway can be targeted for treatment, promises higher specificity at lower drugdoses. The map of the deranged cellular circuit can now define the optimal set of interconnected drug targets. We can predict that some time in the near future these new technology platforms will directly affect clinical practice by impacting on all the critical elements of patient care: from early detection of the disease itself using proteomic pattern signatures in a drop of blood to the individualization of therapeutics based on protein circuit profiling from a small biopsy sample. 18.
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